High Quality NGS Techniques for ctDNA Biomarker Detection in Clinical Trials

Time: 12:15 pm
day: Day One


• Pre-analytical considerations of ctDNA application in Oncology
• FDA-lead SEQC2 study, published on Nature Biotechnology April 2021, provides a reliable basis for clinical experts to select high-quality NGS for the first time, and a referable technical standard for clinical application and large clinical trials of early and advanced cancer patients
• ctDNA-based biomarker detection for therapy selection, response monitoring, minimal residual disease and corresponding NGS solutions of Burning Rock